Triple
T6003723
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | developedDrug |
P73
|
FINISHED |
| Object |
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
|
E561037
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: LOXO-292 | Statement: [Loxo Oncology, developedDrug, LOXO-292]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: LOXO-292 Context triple: [Loxo Oncology, developedDrug, LOXO-292]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: LOXO-292 Triple: [Loxo Oncology, developedDrug, LOXO-292]
Generated description
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: LOXO-292 Target entity description: LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c0560bae148190ad4755defaaf471b |
completed | March 22, 2026, 8:50 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c1088f5c84819094e4696c24c4dd79 |
completed | March 23, 2026, 9:31 a.m. |
| NEDg | Description generation | batch_69c1099f00f88190a5f1f0fafbb679c2 |
completed | March 23, 2026, 9:36 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69c10a2ffdcc8190bfeebc59d98b2b29 |
completed | March 23, 2026, 9:38 a.m. |
Created at: March 22, 2026, 4:06 p.m.